Immune stimulating laser ablation – using new hot technology

The thermal effects on cells depend mainly on two factors – temperature and time. Pre-clinical research done by, amongst others, our co-founder Prof. Karl-Göran Tranberg, has shown that moderate heating of cancerous tumor cells during a long time will kill the targeted tumor itself, and also activate the immune system to attack cancer cells throughout the body.

When cells of a cancerous tumor are moderately heated over time their membranes are cracked. The heated cell then opens and exposes the tumor-specific antigens that were contained within. The body’s immune system reacts to the exposed antigens by producing antibodies can recognize and “flag” these specific tumor antigens anywhere in the body. Thereby the immune system can recognize and attack remaining tumor cells, even those that are outside, or distant from, the treated area. This resulting phenomenon of immune stimulation is called the abscopal effect.

Immune stimulating thermal ablation requires accuracy and precision

Even if the principle is simple, the procedure requires great precision and control. Thermal energy must be accurately guided into the tumor and precisely controlled to generate low, non-coagulating temperatures at the outer surface of the tumor. This causes the cell membranes in this area to open and antigens to be released, creating an immune response that potentially also attacks existing metastases in the body, the abscopal effect.

With the purpose of providing an abscopal effect to be used as a monotherapy or in combination with other cancer immunotherapies in curative treatment of metastasized (spread) cancer, CLS has developed its own specific immune stimulating ablation protocol named imILT®.

TRANBERG® delivers precise and accurate  imILT treatments

The imILT protocol is delivered through a minimally invasive image-guided procedure with the precision and accuracy required using the TRANBERG | Thermal Therapy Systems, with their built-in tissue temperature feedback and control features, integrated with an existing Ultrasound/MR scanner and instrument navigation and positioning system.

Note: The clinical effects when applying the imILT protocol are being investigated and the use of imILT is currently restricted to clinical investigations only.

Contact for more information

Hoda Tawfik
VP Clinical Affairs
Hoda.tawfik@clinicallaser.com

News and insights

28 November, 2022

Clinical data from a Phase II trial using CLS TRANBERG products presented during RSNA 2022 Annual Meeting

The RSNA (Radiological Society of North America) annual meeting is ongoing in Chicago, the US. Yesterday, interim data from the ongoing study in Toronto using CLS´s TRANBERG products, was presented by the principal investigator MD Sangeet Ghai.   

Read more
24 November, 2022

Our CTO Cristina Pantaleone awarded Technician of the Year by the Chamber of Commerce

We are happy to announce that our Chief Technology Officer Cristina Pantaleone today has been awarded Technician of the Year by the Chamber of Commerce and Industry of Southern Sweden.

Read more
8 November, 2022

Scientific presentations related to the use of CLS TRANBERG® products at the 13th iMRI Symposium in Leipzig

We want to highlight a couple of scientific presentations held during the 13th Interventional MRI Symposium 2022 in Leipzig, October 14-15, 2022. This event provides an ideal platform for researchers, clinicians, and healthcare professionals alike to present their latest results within interventional MRI.

Read more

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!


Please choose your country or region

Global
US